Targeting CD20: teaching an old dog new tricks

Por Sharman, Jeff P.
Publicado no Hematology Am Soc Hematol Educ Program (2019)

Effectiveness of Warfarin among Patients with Cancer

Por Rose, Adam J., Sharman, Jeff P., Ozonoff, Al, Henault, Lori E., Hylek, Elaine M.
Publicado em 2007

A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera(®)) in Subjects with Previously Un...

Por Sharman, Jeff P., Liberati, Anna Marina, Ishizawa, Kenichi, Khan, Tahira, Robbins, Jeffery, Alcasid, Ann, Rosenberg, Julie Ann, Aurer, Igor
Publicado no BioDrugs (2019)

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

Por Irish, Jonathan M., Myklebust, June H., Alizadeh, Ash A., Houot, Roch, Sharman, Jeff P., Czerwinski, Debra K., Nolan, Garry P., Levy, Ronald
Publicado em 2010

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

Por Horwitz, Steven M., Advani, Ranjana H., Bartlett, Nancy L., Jacobsen, Eric D., Sharman, Jeff P., O’Connor, Owen A., Siddiqi, Tanya, Kennedy, Dana A., Oki, Yasuhiro
Publicado no Blood (2014)

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

Por Byrd, John C., Flynn, Joseph M., Kipps, Thomas J., Boxer, Michael, Kolibaba, Kathryn S., Carlile, David J., Fingerle-Rowson, Guenter, Tyson, Nicola, Hirata, Jamie, Sharman, Jeff P.
Publicado no Blood (2016)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

Por Andorsky, David J., Kolibaba, Kathryn S., Assouline, Sarit, Forero‐Torres, Andres, Jones, Vicky, Klein, Leonard M., Patel‐Donnelly, Dipti, Smith, Mitchell, Ye, Wei, Shi, Wen, Yasenchak, Christopher A., Sharman, Jeff P.
Publicado no Br J Haematol (2018)

Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin

Por Coffey, Greg P., Rajapaksa, Ranjani, Liu, Raymond, Sharpe, Orr, Kuo, Chiung-Chi, Krauss, Sharon Wald, Sagi, Yael, Davis, R. Eric, Staudt, Louis M., Sharman, Jeff P., Robinson, William H., Levy, Shoshana
Publicado em 2009

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States

Por Nabhan, Chadi, Mato, Anthony, Flowers, Christopher R., Grinblatt, David L., Lamanna, Nicole, Weiss, Mark A., Davids, Matthew S., Swern, Arlene S., Bhushan, Shriya, Sullivan, Kristen, Flick, E. Dawn, Kiselev, Pavel, Sharman, Jeff P.
Publicado no BMC Cancer (2017)

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Por Forero-Torres, Andres, Holkova, Beata, Goldschmidt, Jerome, Chen, Robert, Olsen, Gregg, Boccia, Ralph V., Bordoni, Rodolfo E., Friedberg, Jonathan W., Sharman, Jeff P., Palanca-Wessels, Maria Corinna, Wang, Yinghui, Yasenchak, Christopher A.
Publicado no Blood (2015)

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymph...

Por Sharman, Jeff P., Farber, Charles M., Mahadevan, Daruka, Schreeder, Marshall T., Brooks, Heather D., Kolibaba, Kathryn S., Fanning, Suzanne, Klein, Leonard, Greenwald, Daniel R., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Burke, John M.
Publicado no Br J Haematol (2016)

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

Por Ahn, Inhye E., Farber, Charles M., Davids, Matthew S., Grinblatt, David L., Kay, Neil E., Lamanna, Nicole, Mato, Anthony, Nabhan, Chadi, Kiselev, Pavel, Swern, Arlene S., Flick, E. Dawn, Sullivan, Kristen, Sharman, Jeff P., Flowers, Christopher R.
Publicado no Blood Adv (2017)

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Por Advani, Ranjana H., Buggy, Joseph J., Sharman, Jeff P., Smith, Sonali M., Boyd, Thomas E., Grant, Barbara, Kolibaba, Kathryn S., Furman, Richard R., Rodriguez, Sara, Chang, Betty Y., Sukbuntherng, Juthamas, Izumi, Raquel, Hamdy, Ahmed, Hedrick, Eric, Fowler, Nathan H.
Publicado no J Clin Oncol (2013)

The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites

Por Mato, Anthony, Nabhan, Chadi, Lamanna, Nicole, Kay, Neil E., Grinblatt, David L., Flowers, Christopher R., Farber, Charles M., Davids, Matthew S., Swern, Arlene S., Sullivan, Kristen, Flick, E. Dawn, Gressett Ussery, Sarah M., Gharibo, Mecide, Kiselev, Pavel, Sharman, Jeff P.
Publicado no Blood Adv (2020)

Management of adverse events associated with idelalisib treatment: expert panel opinion

Por Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Publicado no Leuk Lymphoma (2015)

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry

Por Mato, Anthony R., Barrientos, Jacqueline C., Ghosh, Nilanjan, Pagel, John M., Brander, Danielle M., Gutierrez, Meghan, Kadish, Karen, Tomlinson, Brian, Iyengar, Reethi, Ipe, David, Upasani, Sandhya, Amaya-Chanaga, Carlos I., Sundaram, Murali, Han, Jennifer, Giafis, Nick, Sharman, Jeff P.
Publicado no Clin Lymphoma Myeloma Leuk (2019)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Por Coutre, Steven E., Flinn, Ian W., de Vos, Sven, Barrientos, Jacqueline C., Schreeder, Marshall T., Wagner-Johnson, Nina D., Sharman, Jeff P., Boyd, Thomas E., Fowler, Nathan, Dreiling, Lyndah, Kim, Yeonhee, Mitra, Siddhartha, Rai, Kanti, Leonard, John P., Furman, Richard R.
Publicado no Hemasphere (2018)

Real‐world clinical experience in the Connect(®) chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres

Por Mato, Anthony, Nabhan, Chadi, Kay, Neil E., Weiss, Mark A., Lamanna, Nicole, Kipps, Thomas J., Grinblatt, David L., Flinn, Ian W., Kozloff, Mark F., Flowers, Christopher R., Farber, Charles M., Kiselev, Pavel, Swern, Arlene S., Sullivan, Kristen, Flick, E. Dawn, Sharman, Jeff P.
Publicado no Br J Haematol (2016)

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Por de Vos, Sven, Wagner-Johnston, Nina D., Coutre, Steven E., Flinn, Ian W., Schreeder, Marshall T., Fowler, Nathan H., Sharman, Jeff P., Boccia, Ralph V., Barrientos, Jacqueline C., Rai, Kanti R., Boyd, Thomas E., Furman, Richard R., Kim, Yeonhee, Godfrey, Wayne R., Leonard, John P.
Publicado no Blood Adv (2016)

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

Por Sharman, Jeff P., Forero-Torres, Andres, Costa, Luciano J., Flinn, Ian W., Inhorn, Lowell, Kelly, Kevin, Bessudo, Alberto, Fayad, Luis E., Kaminski, Mark S., Evens, Andrew M., Flowers, Christopher R., Sahin, Deniz, Mundt, Kirsten E., Sandmann, Thomas, Fingerle-Rowson, Günter, Vignal, Charlotte, Mobasher, Mehrdad, Zelenetz, Andrew D.
Publicado no Leuk Lymphoma (2018)